Company News »

Akebia to Participate in Upcoming Investor Conferences

Business Wire
Share on StockTwits
Published on

Akebia Therapeutics, Inc. (NASDAQ:AKBA) , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:

  • Presentation at the Nomura Biotechnology Conference on Thursday, November 6, at 11:00 a.m. Eastern Time
  • Presentation at the 2014 Credit Suisse Healthcare Conference on Wednesday, November 12, at 1:30 p.m. Mountain Time

A live audio webcast of the presentations will be available on the company’s website at http://ir.akebia.com/events.cfm. An archived presentation will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia’s lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to CKD in non-dialysis patients and is in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. For more information on Akebia, please visit www.akebia.com.

Share on StockTwits